公司概覽
業務類別 Biotechnology
業務概覽 Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
公司地址 701 Tillery Street No. 12, No.1010, Austin, TX, USA, 78702
電話號碼 +1 240 243-8000
傳真號碼 --
公司網頁 https://www.faeththerapeutics.com
員工數量 29
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Patrick Gallagher Chief Business Officer -- 15/06/2023
Ms. Erin Colgan Chief Financial Officer and Principal Accounting Officer 美元 410.00K 29/02/2024
Mr. Anand Kiran Parikh Director and Chief Operating Officer -- 18/02/2026
Mr. Edward Van der Horst, PhD Chief Scientific Officer 美元 400.00K 11/04/2025
Dr. Robert Pierce Chief Research and Development Officer 美元 410.00K 28/04/2022
Ms. Marie-Louise Fjaellskog Chief Medical Officer -- 30/03/2021
Mr. Christopher W Gerry President, Principal Executive Officer and General Counsel 美元 398.18K 16/04/2026
Ms. Stephanie Krebs Chief Business Officer 美元 385.00K 11/04/2025
Mr. John Celebi President, Chief Executive Officer and Director 美元 535.60K 11/04/2025
Mr. Josiah Craver Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer 美元 372.65K 27/04/2026
Dr. Brian C. Stephenson, PhD Chief Financial Officer -- 10/06/2026
 
董事會成員
董事會 職務 更新日期
Mr. William R. Ringo, Jr Chairman of the Board 11/04/2025
Dr. Deneen Vojta, M.D. Independent Director 30/10/2024
Mr. Anand Kiran Parikh Director and Chief Operating Officer 18/02/2026
Dr. Jessie M. English, PhD Independent Director 27/06/2024
Dr. Samuel Broder,M.D. Independent Director 15/06/2023
Ms. Saira Ramasastry Independent Director 16/04/2026
Mr. Thomas G. Ricks Independent Director 16/04/2026
Mr. Stephen M. Hahn Independent Director 16/04/2026
Mr. Bob Holmen Chairman of the Board 27/04/2026
Mr. Kristian F. Humer Independent Director 16/04/2026
Mr. John Celebi President, Chief Executive Officer and Director 11/04/2025
Mr. Phillip B. Donenberg Director 13/02/2026
Dr. James Peyer, PhD Independent Director 11/04/2025
Dr. Karen H. Vousden, PhD Independent Director 10/06/2026
 
所屬ETF (更新日期: 17/06/2026 02:25)
代號 名稱 佔比% 持有日期
DFASDimensional US Small Cap ETF0.10%29/05/2026
GUGGuggenheim Active Allocation Fund0.0004%30/11/2025
BIBProShares Ultra Nasdaq Biotechnology<0.000001%16/05/2023
DFACDimensional US Core Equity 2 ETF<0.000001%20/09/2023
DFSUDimensional US Sustainability Core 1 ETF<0.000001%24/02/2026
HDGProShares Hedge Replication<0.000001%30/06/2022
IBBiShares Biotechnology ETF<0.000001%22/12/2022
IBBQInvesco Nasdaq Biotechnology ETF<0.000001%19/12/2022
ISCBiShares Morningstar Small-Cap ETF<0.000001%17/12/2021
IWCiShares Micro-Cap ETF<0.000001%02/03/2026
IWMiShares Russell 2000 ETF<0.000001%24/06/2022
IWNiShares Russell 2000 Value ETF<0.000001%24/06/2022
IWOiShares Russell 2000 Growth ETF<0.000001%25/06/2021
RYLDGlobal X Russell 2000 Covered Call ETF<0.000001%27/06/2022
SBIOALPS Medical Breakthroughs ETF<0.000001%17/12/2021
SCHASchwab US Small-Cap ETF™<0.000001%20/09/2021
SMMDiShares Russell 2500 ETF<0.000001%24/06/2022
URTYProShares UltraPro Russell2000<0.000001%30/06/2022
UWMProShares Ultra Russell2000<0.000001%30/06/2022
VTHRVanguard Russell 3000 ETF<0.000001%30/06/2022
 1    2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.